The Journal of Medical Microbiology, Vol 21, Issue 4 299-309, Copyright © 1986 by Society for General Microbiology

JOURNAL ARTICLE

An in-vitro model of colonisation resistance to Clostridium difficile infection

S. P. Borriello and F. E. Barclay

To investigate the importance of the normal gut flora in preventing the establishment of Clostridium difficile in vivo we have developed an in-vitro test system based on growth in faecal emulsions. Growth of C. difficile and cytotoxin production are inhibited in faecal emulsions from healthy adults, but not in sterilised emulsions; the importance of viable bacteria in the inhibitory system is evident. Generally, faecal emulsions derived from infants, children and geriatric patients were less inhibitory than those from healthy adults. Those from bottle-fed infants were significantly less inhibitory than those from breast-fed infants. Decreased levels of cytotoxin in the latter group were attributed to the acidic pH of the stools. With the different patient groups studied, faecal samples not inhibitory to C. difficile in vitro were obtained from 21% of patients with antibiotic-associated diarrhoea, 33% of those taking antibiotics but who did not have diarrhoea, 18.7% of those with diarrhoea unassociated with antibiotics, and 79% of those with C. difficile-mediated diarrhoea. In some cases inhibition was due to low faecal pH, as in some infants, and in others to other filterable substances. The degree of inhibition could not be linked to specific volatile fatty acids or enzymes.

This article has been cited by other articles:

				J. Freeman, S. D. Baines, D. Jabes, and M. H. Wilcox Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection J. Antimicrob. Chemother., October 1, 2005; 56(4): 717 - 725. [Abstract] [Full Text] [PDF]

				S. D. Baines, J. Freeman, and M. H. Wilcox Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model J. Antimicrob. Chemother., June 1, 2005; 55(6): 974 - 982. [Abstract] [Full Text] [PDF]

				M. H. Wilcox, J. Freeman, W. Fawley, S. MacKinlay, A. Brown, K. Donaldson, and O. Corrado Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea J. Antimicrob. Chemother., July 1, 2004; 54(1): 168 - 172. [Abstract] [Full Text] [PDF]

				J. Freeman, F. J. O'Neill, and M. H. Wilcox Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut J. Antimicrob. Chemother., July 1, 2003; 52(1): 96 - 102. [Abstract] [Full Text] [PDF]

				M. J. Hopkins and G. T. Macfarlane Nondigestible Oligosaccharides Enhance Bacterial Colonization Resistance against Clostridium difficile In Vitro Appl. Envir. Microbiol., April 1, 2003; 69(4): 1920 - 1927. [Abstract] [Full Text] [PDF]

				L. J. Drummond, J. McCoubrey, D. G. E. Smith, J. M. Starr, and I. R. Poxton Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period J. Med. Microbiol., March 1, 2003; 52(3): 259 - 263. [Abstract] [Full Text] [PDF]

				A.W. TAYLOR-ROBINSON and D. TAYLOR-ROBINSON Evaluation of liquid culture media to support growth of Mobiluncus species J. Med. Microbiol., June 1, 2002; 51(6): 491 - 494. [Abstract] [Full Text] [PDF]

				M H WILCOX Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors? Thorax, August 1, 2000; 55(8): 633 - 634. [Full Text]